News
News and updates on psilocybin research, policy, and the psychedelic retreat landscape from Retraite Eveil.
Veterans and psilocybin access programs in the US and UK
Veterans and psilocybin access in the US and UK: VA and NHS research realities, state services, and overseas retreats.
Read article →
Psychedelics in hospice care: global pilot programs
Global pilot programmes on psilocybin in hospice and palliative care: what the evidence shows and how it differs from retreat tourism.
Read article →
Climate impact of indoor truffle cultivation: energy and sustainability
Indoor sclerotia cultivation uses HVAC, humidity control, and cold chains. How to think about climate impact without greenwashing.
Read article →
Psychedelic tourism growth in Europe: EMCDDA trend data
What EMCDDA and EU drug-monitoring trends can and cannot say about psychedelic tourism growth in Europe.
Read article →
AI and psychedelic research: simulation, screening, and hype boundaries
AI in psychedelic research: useful screening and logistics versus simulation hype, data scarcity, and regulator expectations in 2026.
Read article →
Psychedelic patents and open science tensions
How psychedelic IP filings clash with open science: prior art projects, USPTO and WIPO pathways, synthesis controversies, and why Dutch sclerotia programmes are not patent medicine...
Read article →
Psychedelic biotech companies in 2026: who is researching what
A 2026 map of psychedelic biotech pipelines: who studies psilocybin, MDMA, DMT, and related compounds, how trials differ from retreat markets, and how to read company claims withou...
Read article →
EU drug agency reports on psilocybin prevalence and harm
EU Drugs Agency reports calibrate psilocybin prevalence and harm without granting retail rights. Learn how to read the tables without slogan science.
Read article →
OECD and WHO perspectives on psychedelic policy harmonization
OECD and WHO shape evidence and governance languages for psychedelic policy. Harmonization can mean shared safety standards, not a world retail switch.
Read article →
Mexico psilocybin mushroom traditions and modern enforcement
Mexico holds living mushroom traditions and modern narcotics enforcement at once. Tourism slogans do not repeal either system.
Read article →
Brazil and ayahuasca vs psilocybin legal contrasts
Brazil's ayahuasca religious recognition does not automatically cover psilocybin. Substance-specific legal contrasts protect travelers and communities from false assumptions.
Read article →
Australia rescheduling psilocybin for therapy: what changed
Australia's rescheduling enabled authorized specialist prescribing under tight conditions. Here is what changed, what did not, and how to avoid tourism myths.
Read article →
Canada psilocybin exemptions and Special Access Program
Canada's exemptions and Special Access Program are real clinical tools, not retail legalization. Learn what they authorize, refuse, and how patients can verify claims.
Read article →
Belgium and truffle tourism: cross border legal notes
Belgium sits beside Dutch sclerotia retail culture, which fuels truffle-tourism myths. Cross-border legal notes explain why Schengen convenience is not a Benelux free-for-all.
Read article →
France and psychedelic research: current academic landscape
France keeps psilocybin tightly controlled while universities and hospitals slowly rebuild psychedelic research capacity. Here is how to read the academic landscape without mistaki...
Read article →
United Kingdom psilocybin rescheduling debates post 2020
Since 2020, UK debate on psilocybin has intensified around Schedule 1 barriers, ACMD advice, and research friction. Here is what rescheduling talk means versus what law still requi...
Read article →
Czech Republic and psychedelic policy overview
The Czech Republic combines active scientific interest in psychedelics with conventional controlled-substance law. This overview separates research culture, political proposals, an...
Read article →
Switzerland's compassionate use and psychedelic trials
Switzerland combines cautious medicines regulation with limited exceptional access and active academic trials. Here is how compassionate use, Swissmedic, and research protocols dif...
Read article →
Germany's psychedelic research funding and pilot programs
Germany’s psychedelic momentum is concentrated in research funding, hospital ethics pathways, and regulator dialogue, not in retail tourism. Here is how BMBF, BfArM, and academic p...
Read article →
Spain psilocybin retreats in legal gray zones: what is actually allowed
Spanish psilocybin retreat marketing often sits in a gray zone between private consumption claims, club narratives, and criminal supply law. Here is what is actually allowed versus...
Read article →
Portugal drug decriminalization and psilocybin: myths vs law
Portugal’s 2001 reform decriminalized personal drug possession, but it did not legalize psilocybin sales or retreat tourism. Here is how the myths diverge from SICAD practice and c...
Read article →
Exporting truffles from the Netherlands: what the law says for tourists
Buying magic truffles in Amsterdam feels straightforward until you pack for the flight home. Dutch tolerance policy governs retail inside the Netherlands. It does not grant travele...
Read article →
Opium Act and psilocybin truffles: the legal text in plain English
The Dutch Opium Act (Opiumwet) is the primary statute governing controlled substances in the Netherlands. For international visitors researching psilocybin retreats, the most pract...
Read article →
FDA breakthrough therapy and psilocybin: current status
What FDA Breakthrough Therapy designation means for psilocybin developers, patients, and how it differs from state service laws.
Read article →
Police encounters and psilocybin in the Netherlands: what statistics show
Headlines about Dutch drug tolerance rarely cite police statistics, yet numbers matter when you assess how often psilocybin actually appears in enforcement data. Official crime tab...
Read article →
Future of Dutch psychedelic policy: decriminalization debates in 2026
Dutch psychedelic policy headlines in 2026 oscillate between codifying truffle tolerance, tightening tourism enforcement, and expanding hospital research access. Parliamentary deba...
Read article →
Schengen rules and psychedelic tourism: staying compliant as a visitor
Psychedelic tourism to the Netherlands often begins with questions about truffles and ends with questions about passports. Schengen compliance governs how long you may remain in Eu...
Read article →
Medical cannabis vs psilocybin truffles in Dutch law: side by side
The Netherlands hosts two radically different legal regimes for psychoactive plants that international visitors often conflate. Medical cannabis moves through pharmacy channels wit...
Read article →
Smart shops vs retreats: legal differences and consumer protection
Smart shops and psilocybin retreats both operate inside Dutch tolerance culture, yet they answer to different legal frameworks, consumer rules, and complaint channels. A counter pu...
Read article →
EMA and European psilocybin medicine pathways
How EMA centralized procedures, national implementation, and HTA shape potential European psilocybin medicine access.
Read article →
Age limits for truffle purchase and retreat participation in the Netherlands
Buying magic truffles at a Dutch smart shop and joining a psilocybin retreat are both legal conversations for adults, yet age rules differ between retail counters and ceremony cont...
Read article →
Psychedelic Retreats in Europe: Why the Netherlands Is the Safest and Most Accessible Destination
Psychedelic retreats are attracting more and more people across Europe who are looking for a legal, safe, and professional setting to explore psilocybin responsibly. Among all poss...
Read article →
Valeriia Akatova: From Kyiv Under Fire to Guide at Retraite Eveil and Co-Founder of Foundation Ukraine
Valeriia Akatova is a living example of resilience and transformation. Born in January 1993 in Ukraine, she lived through the horror of war in Kyiv in February 2022, fled with her...
Read article →
What the Trump Order to Allow Research on Psychedelic Drugs for Medical Purposes Means for Psychedelic Aficionados
On April 18, 2026, President Donald Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness.” This directive instructs federal agencies t...
Read article →